Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones

FILANA THERAPEUTICS, INC.

Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.
Financial terms: nominal upfront, up to $4.5M in clinical/regulatory/commercial milestones, tiered low-to-mid single-digit % royalties on net sales.
Based on Yale research (Bordey et al., Science Translational Medicine 2020) showing simufilam reduced seizure frequency in an animal model.
Cassava to prioritize initial development on TSC-related seizures and plans preclinical studies with the TSC Alliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.